1. Home
  2. LAES vs TRDA Comparison

LAES vs TRDA Comparison

Compare LAES & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SEALSQ Corp

LAES

SEALSQ Corp

HOLD

Current Price

$4.02

Market Cap

366.0M

Sector

Technology

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$11.03

Market Cap

386.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAES
TRDA
Founded
2022
2016
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
366.0M
386.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
LAES
TRDA
Price
$4.02
$11.03
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$6.00
$20.00
AVG Volume (30 Days)
14.4M
242.4K
Earning Date
12-11-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,978,000.00
$61,520,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.16
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.48
$4.93
52 Week High
$11.00
$19.93

Technical Indicators

Market Signals
Indicator
LAES
TRDA
Relative Strength Index (RSI) 39.70 73.90
Support Level $4.45 $10.40
Resistance Level $5.09 $11.24
Average True Range (ATR) 0.38 0.54
MACD 0.01 -0.00
Stochastic Oscillator 10.81 86.96

Price Performance

Historical Comparison
LAES
TRDA

About LAES SEALSQ Corp

SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: